Translational precision medicine: an industry perspective.

Journal: Journal of translational medicine
Published Date:

Abstract

In the era of precision medicine, digital technologies and artificial intelligence, drug discovery and development face unprecedented opportunities for product and business model innovation, fundamentally changing the traditional approach of how drugs are discovered, developed and marketed. Critical to this transformation is the adoption of new technologies in the drug development process, catalyzing the transition from serendipity-driven to data-driven medicine. This paradigm shift comes with a need for both translation and precision, leading to a modern Translational Precision Medicine approach to drug discovery and development. Key components of Translational Precision Medicine are multi-omics profiling, digital biomarkers, model-based data integration, artificial intelligence, biomarker-guided trial designs and patient-centric companion diagnostics. In this review, we summarize and critically discuss the potential and challenges of Translational Precision Medicine from a cross-industry perspective.

Authors

  • Dominik Hartl
    Novartis Institutes for BioMedical Research, Basel, Switzerland. dominik.hartl@novartis.com.
  • Valeria de Luca
    Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Anna Kostikova
    Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Jason Laramie
    Novartis Institutes for BioMedical Research, Cambridge, MA, USA.
  • Scott Kennedy
    Novartis Institutes for BioMedical Research, Cambridge, MA, USA.
  • Enrico Ferrero
    Computational Biology and Stats, Target Sciences, GlaxoSmithKline, Stevenage, UK.
  • Richard Siegel
    Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Martin Fink
    Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Sohail Ahmed
    , Basel, Switzerland.
  • John Millholland
    Novartis Precision Medicine, Cambridge, MA, USA.
  • Alexander Schuhmacher
    Reutlingen University, Alteburgstrasse 150, 72762, Reutlingen, Germany. Electronic address: alexander.schuhmacher@reutlingen-university.de.
  • Markus Hinder
    Novartis Institute of BioMedical Research, Postfach, Forum 1, 4002, Basel, Switzerland. Electronic address: markus.hinder@novartis.com.
  • Luca Piali
    Roche Innovation Center Basel, Basel, Switzerland.
  • Adrian Roth
    Roche Innovation Center Basel, Basel, Switzerland.